Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 11/20 | 0.42 |
| ▸ | YAP1 | P46937 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 3/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 4/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4124707 | 0.91 | ACHE (0.44) | ACHEYAP1BCHEKDM1APREP | |
| SCHEMBL4126759 | 0.91 | ACHE (0.45) | ACHEBCHETRPM8 | |
| SCHEMBL4122307 | 0.91 | GPR119 (0.43) | ACHEYAP1GPR119 | |
| SCHEMBL4114201 | 0.90 | ACHE (0.48) | ACHEBCHE | |
| SCHEMBL4126858 | 0.90 | ACHE (0.39) | ACHEBCHEKDM1ACHRM4 | |
| SCHEMBL4129360 | 0.90 | ACHE (0.41) | ACHEYAP1BCHEKDM1APREP | |
| SCHEMBL4119841 | 0.90 | ACHE (0.38) | ACHEBCHEGPR119CHRM4 | |
| SCHEMBL4126868 | 0.90 | ACHE (0.42) | ACHEBCHEKDM1AKCNH2 | |
| SCHEMBL4131954 | 0.90 | ACHE (0.42) | ACHEBCHEPREP | |
| SCHEMBL4120498 | 0.88 | ACHE (0.58) | ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-2017275-A1 | BENZISOXAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | NR1I2, NR1I3, NR0B1 | ACHE 3716/4885YAP1 3743/4885BCHE 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.